TRAWS PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.67 USD | -3.69% |
|
-6.10% | -10.14% |
| Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
| Apr. 04 | Traws Pharma, Inc. Announces Chief Executive Office Changes | CI |
Financials (USD)
| Sales 2024 * | 210K | Sales 2025 * | 300K | Capitalization | 14.67M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M | Net income 2025 * | -28M | EV / Sales 2024 * | 69.9 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 48.9 x |
| P/E ratio 2024 * |
-0.8
x | P/E ratio 2025 * |
-0.84
x | Employees | 18 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on Traws Pharma, Inc.
More recommendations
More press releases
| 1 day | +1.90% | ||
| 1 week | -11.54% | ||
| Current month | -31.12% | ||
| 1 month | -20.03% | ||
| 3 months | +0.62% | ||
| 6 months | +7.20% | ||
| Current year | -6.69% |
1 week
0.65
0.73
1 month
0.651.10
Current year
0.651.10
1 year
0.551.45
3 years
0.5516.50
5 years
0.5566.75
10 years
0.5514 107.51
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 13-08-31 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 15-06-30 |
Jack Stover
BRD | Director/Board Member | 69 | 16-05-22 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 20-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.67 | -3.69% | 30 401 |
| 24-04-18 | 0.6957 | +1.90% | 34,280 |
| 24-04-17 | 0.6827 | -1.93% | 102,226 |
| 24-04-16 | 0.6961 | -3.08% | 23,577 |
| 24-04-15 | 0.7182 | +0.66% | 55,050 |
Delayed Quote Nasdaq, April 18, 2024 at 04:30 pm EDT
More quotes
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclibâs mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.6957
USD
Average target price
8
USD
Spread / Average Target
+1,049.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.69% | 14.67M | |
| -1.82% | 41.35B | |
| +41.53% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- TRAW Stock
